ERBB2 and neoplasm: The observation of HER2 amplification exclusively in disseminated cells, suggests a selection of clones within the primary tumour that harboured initial HER2 amplification and that were underrepresented in the primary tumour, for example, by cytotoxic agents, rather than an acquisition of this amplification de novo within the metastatic cells.